Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments

Özet

The Food and Drug Administration (FDA or we) announces a forthcoming public advisory committee meeting of the Vaccines and Related Biological Products Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The Committee will discuss Considerations for Respiratory Syncytial Virus (RSV) Vaccine Safety in Pediatric Populations and will also hear overviews of the Laboratory of Immunoregulation (LI) and Laboratory of Retroviruses (LR) research programs in the Center for Biologics Evaluation and Research. At least one portion of the meeting will be closed to the public. FDA is establishing a docket for public comment on this document.